Company: CERO
Filing Date: 2025-02-13
Form Type: 424B3
Source: 0001213900-25-013495
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-13
Form: 424B3
Chunk 4
---
 occur on February 7, 2025. The Company expects to receive gross proceeds of approximately $5 million, before deducting the estimated offering expenses payable by the Company, including the Placement Agent and financial advisory fees. The Company intends to use the net proceeds from the Offering for advancement of its clinical programs and working capital and other general corporate purposes.

The foregoing summaries of the Placement Agency Agreement, the Warrants and the Purchase Agreement do not purport to be complete and are subject to, and qualified in their entirety by, the forms of such documents, which are filed as exhibits 1.1, 4.1 and 10.1 to this Current Report on Form 8-K, respectively, which are incorporated by reference.

Item 8.01 Other Events.

The Company issued a press release announcing the pricing of the Offering on February 5, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit 
 Number  
 1.1     |     | Description                                                                                                       
 Placement Agency Agreement, dated February 5, 2025 by and between the Company and A.G.P./Alliance Global Partners |
|:--------|:----|:------------------------------------------------------------------------------------------------------------------|
| 4.1     |     | Form of Common Warrant                                                                                            |
| 10.1    |     | Form of Securities Purchase Agreement by and between the Company and the investors named therein.                 |
| 99.1    |     | Press Release (Pricing) dated February 5, 2025                                                                    |
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document)                                       |

<div align='center'>2

SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: February 6, 2025 | CERo Therapeutics 
 Holdings, Inc.    
 By:               | /s/ Chris Ehrlich       |
|:-----------------------|:------------------|:------------------------|
|                        |                   | Chris Ehrlich           |
|                        |                   | Chief Executive Officer |

<div align='center'>3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT